List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/696253/publications.pdf Version: 2024-02-01



SAM CANDY

#	Article	IF	CITATIONS
1	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	7.7	19
2	Cognitive impairment and World Trade Centre-related exposures. Nature Reviews Neurology, 2022, 18, 103-116.	10.1	18
3	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer's disease. Nature Communications, 2022, 13, 159.	12.8	42
4	New developments of biofluidâ€based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 2292-2307.	0.8	14
5	A Letter Concerning "Aducanumab: What about the Patient?â€: Annals of Neurology, 2022, 91, 732-733.	5.3	3
6	Reduced cerebellar cortical thickness in World Trade Center responders with cognitive impairment. Translational Psychiatry, 2022, 12, 107.	4.8	8
7	Making the Case for Accelerated Withdrawal of Aducanumab. Journal of Alzheimer's Disease, 2022, 87, 1003-1007.	2.6	19
8	World Trade Center dust induces nasal and neurological tissue injury while propagating reduced olfaction capabilities and increased anxiety behaviors. Inhalation Toxicology, 2022, , 1-14.	1.6	3
9	Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. Molecular Psychiatry, 2021, 26, 5940-5954.	7.9	56
10	Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer's Disease. Neuron, 2021, 109, 257-272.e14.	8.1	108
11	Reactive or transgenic increase in microglial TYROBP reveals a TREM2â€independent TYROBP–APOE link in wildâ€ŧype and Alzheimer'sâ€related mice. Alzheimer's and Dementia, 2021, 17, 149-163.	0.8	30
12	Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets. Science Advances, 2021, 7, .	10.3	137
13	Selective hippocampal subfield volume reductions in World Trade Center responders with cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12165.	2.4	10
14	A cortical thinning signature to identify World Trade Center responders with possible dementia. Intelligence-based Medicine, 2021, 5, 100032.	2.4	5
15	Laterality and region-specific tau phosphorylation correlate with PTSD-related behavioral traits in rats exposed to repetitive low-level blast. Acta Neuropathologica Communications, 2021, 9, 33.	5.2	7
16	White Matter Connectivity in Incident Mild Cognitive Impairment: A Diffusion Spectrum Imaging Study of World Trade Center Responders at Midlife. Journal of Alzheimer's Disease, 2021, 80, 1209-1219.	2.6	7
17	Alzheimer mutant speeds APP transport. Journal of Experimental Medicine, 2021, 218, .	8.5	2
18	Progressive Cognitive and Post-Traumatic Stress Disorder-Related Behavioral Traits in Rats Exposed to Repetitive Low-Level Blast. Journal of Neurotrauma, 2021, 38, 2030-2045.	3.4	19

#	Article	IF	CITATIONS
19	Repetitive Low-Level Blast Exposure Improves Behavioral Deficits and Chronically Lowers AÎ ² 42 in an Alzheimer Disease Transgenic Mouse Model. Journal of Neurotrauma, 2021, 38, 3146-3173.	3.4	11
20	A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population. International Journal of Environmental Research and Public Health, 2021, 18, 681.	2.6	10
21	Low-level blast exposure induces chronic vascular remodeling, perivascular astrocytic degeneration and vascular-associated neuroinflammation. Acta Neuropathologica Communications, 2021, 9, 167.	5.2	21
22	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA. Molecular Neurodegeneration, 2021, 16, 74.	10.8	10
23	Cortical complexity in world trade center responders with chronic posttraumatic stress disorder. Translational Psychiatry, 2021, 11, 597.	4.8	7
24	Transcranial Laser Therapy Does Not Improve Cognitive and Post-Traumatic Stress Disorder–Related Behavioral Traits in Rats Exposed to Repetitive Low-Level Blast Injury. Neurotrauma Reports, 2021, 2, 548-563.	1.4	2
25	miR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer's disease. Acta Neuropathologica, 2020, 140, 295-315.	7.7	23
26	Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease. Nature Communications, 2020, 11, 3942.	12.8	94
27	Pathway Analysis for Plasma β-Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife. Neurology and Therapy, 2020, 9, 159-171.	3.2	20
28	VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice. Molecular Neurodegeneration, 2020, 15, 4.	10.8	52
29	Incidence of mild cognitive impairment in World Trade Center responders: Longâ€ŧerm consequences of reâ€experiencing the events on 9/11/2001. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 628-636.	2.4	47
30	Paul Greengard, Ph.D. (1925â \in 2019). Alzheimer's and Dementia, 2019, 15, 1229-1235.	0.8	1
31	Low-level blast exposure disrupts gliovascular and neurovascular connections and induces a chronic vascular pathology in rat brain. Acta Neuropathologica Communications, 2019, 7, 6.	5.2	75
32	Relationship of traumatic brain injury to chronic mental health problems and dementia in military veterans. Neuroscience Letters, 2019, 707, 134294.	2.1	42
33	Posttraumatic stress disorder and total amyloid burden and amyloidâ€Î² 42/40 ratios in plasma: Results from a pilot study of World Trade Center responders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 216-220.	2.4	22
34	Unexpected systemic phenotypes result from focal combined deficiencies of forebrain insulin receptor/IGF-1 receptor signaling. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5852-5854.	7.1	0
35	Decrease in p3â€Alcβ37 and p3â€Alcβ40, products of Alcadein β generated by γâ€secretase cleavages, in aged monkeys and patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 740-750.	3.7	6
36	Clarifying the Potential Role of Microbes in Alzheimer's Disease. Neuron, 2019, 104, 1036-1037.	8.1	10

SAM GANDY

#	Article	IF	CITATIONS
37	Blast-induced "PTSD": Evidence from an animal model. Neuropharmacology, 2019, 145, 220-229.	4.1	34
38	Integrative approach to sporadic Alzheimer's disease:Âdeficiency of TYROBPÂin cerebral Aβ amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing Aβ burden. Molecular Psychiatry, 2019, 24, 431-446.	7.9	67
39	Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Molecular Psychiatry, 2019, 24, 1383-1397.	7.9	46
40	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews Neurology, 2018, 14, 168-181.	10.1	905
41	Integrated biology approach reveals molecular and pathological interactions among Alzheimer's Aβ42, Tau, TREM2, and TYROBP in Drosophila models. Genome Medicine, 2018, 10, 26.	8.2	23
42	Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron, 2018, 99, 64-82.e7.	8.1	558
43	iPSC-derived familial Alzheimer's PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling. Molecular Neurodegeneration, 2018, 13, 33.	10.8	35
44	The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Scientific Data, 2018, 5, 180185.	5.3	320
45	PTSD-Related Behavioral Traits in a Rat Model of Blast-Induced mTBI Are Reversed by the mGluR2/3 Receptor Antagonist BCI-838. ENeuro, 2018, 5, ENEURO.0357-17.2018.	1.9	47
46	Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology. Acta Neuropathologica, 2017, 134, 769-788.	7.7	85
47	Directed Differentiation of Human Pluripotent Stem Cells to Microglia. Stem Cell Reports, 2017, 8, 1516-1524.	4.8	260
48	CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 N141I neurons. Acta Neuropathologica Communications, 2017, 5, 77.	5.2	102
49	Midlife interventions are critical in prevention, delay, or improvement of Alzheimer's disease and vascular cognitive impairment and dementia. F1000Research, 2017, 6, 413.	1.6	9
50	Complex mechanisms linking neurocognitive dysfunctionÂto insulin resistance and other metabolic dysfunction. F1000Research, 2016, 5, 353.	1.6	68
51	Alzheimer's Disease and Frontotemporal Dementia. , 2016, , 295-306.		0
52	Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1. Acta Neuropathologica Communications, 2016, 4, 16.	5.2	24
53	Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e237.	6.0	39
54	Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. Genome Medicine, 2016, 8, 104.	8.2	224

#	Article	IF	CITATIONS
55	Memory Loss and Dementia. , 2016, , 93-101.		0
56	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
57	Increased dementia risk following androgen deprivation therapy?. Nature Reviews Urology, 2016, 13, 188-189.	3.8	4
58	Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. Alzheimer's and Dementia, 2016, 12, 851-861.	0.8	85
59	Accelerating stem cell trials for Alzheimer's disease. Lancet Neurology, The, 2016, 15, 219-230.	10.2	76
60	"White Paper―meeting summary and catalyst for future inquiry:ÂComplex mechanisms linking neurocognitive dysfunctionÂto insulin resistance and other metabolic dysfunction. F1000Research, 2016, 5, 353.	1.6	69
61	Repetitive concussions — How dangerous are they?. Molecular and Cellular Neurosciences, 2015, 66, 73-74.	2.2	0
62	Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions. Nature Reviews Neurology, 2015, 11, 230-244.	10.1	65
63	Solanezumab—prospects for meaningful interventions in AD?. Nature Reviews Neurology, 2015, 11, 669-670.	10.1	13
64	Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11965-11970.	7.1	111
65	Physiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1â^'/â^' phenotype and forms complexes with wildtype PS1 and nicastrin. Scientific Reports, 2015, 5, 17042.	3.3	4
66	Characterization and Molecular Profiling of PSEN1 Familial Alzheimer's Disease iPSC-Derived Neural Progenitors. PLoS ONE, 2014, 9, e84547.	2.5	148
67	Chronic traumatic encephalopathy: clinicalâ€biomarker correlations and current concepts in pathogenesis. Molecular Neurodegeneration, 2014, 9, 37.	10.8	54
68	Early fear memory defects are associated with altered synaptic plasticity and molecular architecture in the TgCRND8 Alzheimer's disease mouse model. Journal of Comparative Neurology, 2014, 522, 2319-2335.	1.6	33
69	Environmental Exposures and the Risk for Alzheimer Disease. JAMA Neurology, 2014, 71, 273.	9.0	26
70	Alzheimer's Disease: New Data Highlight Nonneuronal Cell Types and the Necessity for Presymptomatic Prevention Strategies. Biological Psychiatry, 2014, 75, 553-557.	1.3	11
71	[18F]-T807 tauopathy PET imaging in chronic traumatic encephalopathy. F1000Research, 2014, 3, 229.	1.6	26
72	2012: the year in dementia. Lancet Neurology, The, 2013, 12, 4-6.	10.2	7

#	Article	IF	CITATIONS
73	CR1 and the "Vanishing Amyloid―Hypothesis of Alzheimer's Disease. Biological Psychiatry, 2013, 73, 393-395.	1.3	20
74	Toward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress. Annual Review of Medicine, 2013, 64, 367-383.	12.2	89
75	Protein Sorting Motifs in the Cytoplasmic Tail of SorCS1 Control Generation of Alzheimer's Amyloid-β Peptide. Journal of Neuroscience, 2013, 33, 7099-7107.	3.6	40
76	Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nature Reviews Neurology, 2013, 9, 192-200.	10.1	240
77	Latrepirdine (Dimebon [®]), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy, 2013, 9, 617-618.	9.1	95
78	Microglia as Dynamic and Essential Components of the Amyloid Hypothesis. Neuron, 2013, 78, 575-577.	8.1	64
79	Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 864-866.	27.0	38
80	<i>APOE</i> ε4 Status and Traumatic Brain Injury on the Gridiron or the Battlefield. Science Translational Medicine, 2012, 4, 134ed4.	12.4	29
81	The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer's disease. Molecular Neurodegeneration, 2012, 7, 58.	10.8	28
82	Multiple Î ³ -secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects. Molecular Neurodegeneration, 2012, 7, 16.	10.8	14
83	Rapid doubling of Alzheimer's amyloid-β40 and 42 levels in brains of mice exposed to a nickel nanoparticle model of air pollution. F1000Research, 2012, 1, 70.	1.6	52
84	Coordinated increase of Î ³ -secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: quantitative analysis of p3-Alcα with a new ELISA system. Molecular Neurodegeneration, 2011, 6, 76.	10.8	10
85	Alternative processing of γâ€secretase substrates in common forms of mild cognitive impairment and alzheimer's disease: Evidence for γâ€secretase dysfunction. Annals of Neurology, 2011, 69, 1026-1031.	5.3	40
86	Apomorphine and Alzheimer Aβ: Roles for regulated α cleavage, autophagy, and antioxidation?. Annals of Neurology, 2011, 69, 221-225.	5.3	12
87	Perspective: Prevention is better than cure. Nature, 2011, 475, S15-S15.	27.8	53
88	Chromatin plasticity and the pathogenesis of Huntington disease. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16867-16868.	7.1	5
89	Amyloidâ€Î² Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 43-49	1.9	108
90	Testing the amyloid hypothesis of Alzheimer's disease in vivo. Lancet Neurology, The, 2010, 9, 333-335.	10.2	15

SAM GANDY

#	Article	IF	CITATIONS
91	Days to criterion as an indicator of toxicity associated with human Alzheimer amyloidâ€Î² oligomers. Annals of Neurology, 2010, 68, 220-230.	5.3	123
92	Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid β ₄₂ from Isolated Intact Nerve Terminals. Journal of Neuroscience, 2010, 30, 3870-3875.	3.6	78
93	Traumatic Brain Injury — Football, Warfare, and Long-Term Effects. New England Journal of Medicine, 2010, 363, 1293-1296.	27.0	292
94	Diabetes-Associated SorCS1 Regulates Alzheimer's Amyloid-β Metabolism: Evidence for Involvement of SorL1 and the Retromer Complex. Journal of Neuroscience, 2010, 30, 13110-13115.	3.6	139
95	Alcadein Cleavages by Amyloid β-Precursor Protein (APP) α- and γ-Secretases Generate Small Peptides, p3-Alcs, Indicating Alzheimer Disease-related γ-Secretase Dysfunction. Journal of Biological Chemistry, 2009, 284, 36024-36033.	3.4	46
96	<i>APOE</i> ε4 and bapineuzumab. Neurology, 2009, 73, 2052-2053.	1.1	22
97	Dietary composition modulates brain mass and solubilizable Aβ levels in a mouse model of aggressive Alzheimer's amyloid pathology. Molecular Neurodegeneration, 2009, 4, 40.	10.8	43
98	Formation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia. Nature Neuroscience, 2009, 12, 1361-1363.	14.8	390
99	Enhanced generation of Alzheimer's amyloidâ€Î² following chronic exposure to phorbol ester correlates with differential effects on alpha and epsilon isozymes of protein kinase C. Journal of Neurochemistry, 2009, 108, 319-330.	3.9	32
100	X11 Proteins Regulate the Translocation of Amyloid β-Protein Precursor (APP) into Detergent-resistant Membrane and Suppress the Amyloidogenic Cleavage of APP by β-Site-cleaving Enzyme in Brain. Journal of Biological Chemistry, 2008, 283, 35763-35771.	3.4	60
101	Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. Journal of Neurochemistry, 2007, 102, 619-626.	3.9	23
102	Sorting through the Cell Biology of Alzheimer's Disease: Intracellular Pathways to Pathogenesis. Neuron, 2006, 52, 15-31.	8.1	295
103	Alzheimer disease: presenilin springs a leak. Nature Medicine, 2006, 12, 1121-1123.	30.7	14
104	The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. Journal of Clinical Investigation, 2005, 115, 1121-1129.	8.2	238
105	Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nature Medicine, 1998, 4, 447-451.	30.7	545
106	Generation and Regulation of βâ€Amyloid Peptide Variants by Neurons. Journal of Neurochemistry, 1998, 71, 1920-1925.	3.9	111
107	Increased apolipoprotein E ?4 in epilepsy with senile plaques. Annals of Neurology, 1997, 41, 402-404.	5.3	90
108	Apolipoprotein E ?4 and fatal cerebral amyloid angiopathy associated with dementia pugilistica. Annals of Neurology, 1995, 38, 698-699.	5.3	53

SAM GANDY

#	Article	IF	CITATIONS
109	Regulated Formation of Golgi Secretory Vesicles Containing Alzheimer β-Amyloid Precursor Protein. Journal of Biological Chemistry, 1995, 270, 23243-23245.	3.4	149
110	Processing of Alzheimer Aβ-Amyloid Precursor Protein: Cell Biology, Regulation, and Role in Alzheimer Disease. International Review of Neurobiology, 1994, 36, 29-50.	2.0	46
111	Case Report: A World Trade Center (WTC) responder presenting with moderate stage dementia by age 57, suggesting an extended severity of WTC-associated illness'. , 0, , .		0